

A Landscape of Care



DURDANS
HOSPITAL

FINANCIAL STATEMENTS
CEYLON HOSPITALS PLC

FOR THE 4TH QUARTER ENDED 31ST MARCH 2024


Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Group		Company		Group		Company	
	03 Months Ended 31/03/2024	03 Months Ended 31/03/2023	03 Months Ended 31/03/2024	03 Months Ended 31/03/2023	12 Months Ended 31/03/2024	12 Months Ended 31/03/2023	12 Months Ended 31/03/2024	12 Months Ended 31/03/2023
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Unaudited Rs. '000	Audited Rs. '000	Unaudited Rs. '000	Audited Rs. '000
Revenue	2,361,327	2,150,801	1,418,250	1,173,372	9,152,568	7,905,210	5,369,409	4,369,878
Cost of Sales	(921,754)	(759,960)	(569,063)	(394,440)	(4,013,929)	(3,094,517)	(2,417,850)	(1,768,561)
Gross Profit	1,439,573	1,390,841	849,187	778,932	5,138,639	4,810,693	2,951,559	2,601,317
Other Operating Income	52,916	60,556	30,259	15,773	206,808	111,098	78,567	47,366
Administrative Expenses	(839,995)	(837,966)	(540,893)	(535,703)	(3,301,863)	(2,877,830)	(2,061,354)	(1,803,783)
Other Operating Expenses	(404,692)	(367,779)	(238,787)	(158,009)	(1,338,362)	(1,102,987)	(698,668)	(523,774)
Results from Operating Activities	247,802	245,652	99,766	100,993	705,222	940,974	270,104	321,126
Finance Cost	(33,852)	(33,056)	(46,026)	(22,308)	(144,669)	(87,898)	(147,984)	(61,999)
Finance Income	20,444	4,146	654	(25,772)	112,883	207,248	171,816	294,804
Profit before Taxation	234,394	216,742	54,394	52,913	673,436	1,060,324	293,936	553,931
Taxation	(14,803)	(152,173)	14,432	(142,895)	(209,787)	(408,655)	(61,464)	(254,694)
Net Profit after Taxation	219,591	64,569	68,826	(89,982)	463,649	651,669	232,472	299,237
Other Comprehensive Income								
Items will not be reclassified to profit or loss								
Net Change in Fair Value on Equity Investments at FVTOCI	(3,187)	7,041	(4,950)	(646)	(1,466)	12,198	(6,971)	5,712
Actuarial Gain/(Loss) on Gratuity Valuation	408	(17,931)	1,931	(15,640)	408	(17,931)	1,931	(15,640)
Deferred Tax Charge on Actuarial Gain/(Loss) on Gratuity Valuation	579	5,379	579	4,692	579	5,141	579	4,692
Deferred Tax (charge)/Reversal on Revaluation Surplus	-	(127,828)	-	(115,721)	-	(403,509)	-	(390,880)
Other Comprehensive Income for the period	(2,200)	(133,339)	(2,440)	(127,315)	(479)	(404,101)	(4,461)	(396,116)
Total Comprehensive Income for the period	217,391	(68,770)	66,386	(217,297)	463,170	247,568	228,011	(96,879)
Profit Attributable to:								
Equity Holders of the Parent	206,201	45,058	68,826	(89,982)	424,942	571,831	232,472	299,237
Non-Controlling Interest	13,390	19,511	-	-	38,707	79,838	-	-
	219,591	64,569	68,826	(89,982)	463,649	651,669	232,472	299,237
Total Comprehensive Income Attributable to:								
Equity Holders of the Parent	203,933	(87,190)	66,386	(217,297)	423,691	168,992	228,011	(96,879)
Non-Controlling Interest	13,458	18,420	-	-	39,479	78,576	-	-
	217,391	(68,770)	66,386	(217,297)	463,170	247,568	228,011	(96,879)
Earnings per Share - Basic	5.73	1.33	1.91	(2.66)	11.81	16.88	6.46	8.83


The above figures are provisional and subject to audit.


	GROUP		COMPANY	
	Unaudited As at 31/03/2024 Rs. '000	Audited As at 31/03/2023 Rs. '000	Unaudited As at 31/03/2024 Rs. '000	Audited As at 31/03/2023 Rs. '000
ASSETS				
Non-Current Assets				
Property, Plant and Equipment	11,555,666	7,705,992	8,241,211	4,639,970
Capital Work in Progress	72,479	2,604,471	66,091	2,592,874
Intangible Assets	1,600	-	-	-
Right of Use Assets	363,571	261,135	363,571	261,135
Investments in Subsidiary	-	-	1,457,821	1,457,821
Other Financial Assets	289,393	286,005	107,870	79,181
	12,282,709	10,857,603	10,236,564	9,030,981
Current Assets				
Inventories	840,793	1,020,132	642,259	807,593
Trade and Other Receivables	312,866	277,121	199,904	154,800
Prepayments	291,390	726,559	164,155	378,560
Amount Due from Related Parties	5,385	5,329	66,372	37,699
Other Financial Assets	888,205	789,484	45,529	40,686
Tax Refund Due	18,995	13,607	37,260	13,262
Cash and Cash Equivalents	371,006	420,519	211,154	275,221
	2,728,640	3,252,751	1,366,633	1,707,821
Total Assets	15,011,349	14,110,354	11,603,197	10,738,802
EQUITY AND LIABILITIES				
Equity Attributable to Equity holders of the parent				
Stated Capital	1,142,798	1,142,798	1,142,798	1,142,798
Revaluation Reserve	2,290,344	2,290,344	1,742,664	1,742,664
Fair Value Reserve	74,341	76,844	(659)	6,312
Revenue Reserves	4,604,725	4,261,864	2,963,955	2,812,305
	8,112,208	7,771,850	5,848,758	5,704,079
Non-Controlling Interests	735,178	729,500	-	-
Total Equity	8,847,386	8,501,350	5,848,758	5,704,079
Non-Current Liabilities				
Interest Bearing Loans and Borrowings	2,268,138	2,135,972	2,151,998	1,958,282
Deferred Revenue	-	-	28,579	30,470
Retirement Benefit Obligations	227,265	205,414	203,793	182,727
Deferred Tax Liabilities	1,373,362	1,301,996	1,063,004	1,004,120
Amount Due to Related Parties	-	-	467,500	510,000
	3,868,765	3,643,382	3,914,874	3,685,599
Current Liabilities				
Bank Overdraft	542,805	483,403	413,050	387,321
Interest Bearing Loans and Borrowings	609,043	520,602	549,345	478,038
Trade and Other Payables	1,012,959	879,180	550,052	436,695
Taxation Payable	-	82,437	-	35,164
Amount Due to Related Parties	130,393	-	327,119	11,906
	2,295,200	1,965,622	1,839,566	1,349,124
Total Equity and Liabilities	15,011,349	14,110,354	11,603,197	10,738,802

The above figures are provisional and subject to audit.


Thusitha Rubasinghe
Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.
Signed for and on behalf of the Board by,


A E Tudawe
Chairman


U D Tudawe
Director

29th May 2024

CEYLON HOSPITALS PLC
Consolidated Statement of Changes in Equity

Group

	Attributable to equity holders of the parent					Non-Controlling Interests	Total Equity
	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000		
Balance as at 31st March 2022	916,366	2,691,662	65,868	3,873,950	7,547,846	734,254	8,282,100
Net Profit for the Year	-	-	-	571,831	571,831	79,838	651,669
Other Comprehensive Income							
Deferred Tax Effect on Revaluation Gain	-	(401,318)	-	-	(401,318)	(2,191)	(403,509)
Actuarial Gain on Gratuity Valuation	-	-	-	(17,562)	(17,562)	(368)	(17,930)
Deferred Tax effect on Gratuity Valuation	-	-	-	5,065	5,065	76	5,141
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	10,976	-	10,976	1,222	12,198
Total Comprehensive Income for the Year	-	(401,318)	10,976	559,334	168,991	78,577	247,568
Transactions with Owners in their capacity as Owners							
Shares issued at Rights Issue	226,432	-	-	-	226,432	-	226,432
Rights Issue Expenses	-	-	-	(2,056)	(2,056)	-	(2,056)
Shares issued by the Subsidiary at Rights Issue	-	-	-	-	-	5,860	5,860
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(89,190)	(258,554)
	226,432	-	-	(171,420)	55,012	(83,330)	(28,318)
Balance as at 31st March 2023 - Audited	1,142,798	2,290,344	76,844	4,261,864	7,771,850	729,501	8,501,350
Net Profit for the year ended 31 March 2024	-	-	-	424,942	424,942	38,707	463,649
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,503)	-	(2,503)	1,037	(1,466)
Actuarial Gain on Gratuity Valuation	-	-	-	673	673	(265)	408
Deferred Tax Effect on Revaluation Gain	-	-	-	-	-	-	-
Deferred Tax effect on Gratuity Valuation	-	-	-	579	579	-	579
Total Comprehensive Income for the year ended 31 March 2024	-	-	(2,503)	426,194	423,691	39,479	463,170
Transactions with Owners in their capacity as Owners							
Rights Issue Expenses	-	-	-	(557)	(557)	-	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)	(33,802)	(116,578)
	-	-	-	(83,333)	(83,333)	(33,802)	(117,135)
Balance as at 31st March 2024	1,142,798	2,290,344	74,341	4,604,725	8,112,208	735,178	8,847,386

Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Revenue Reserves Rs. '000	Total Rs. '000
Balance as at 31st March 2022	916,366	2,134,544	600	2,695,436	5,746,946
Net Profit for the Year	-	-	-	299,238	299,238
Other Comprehensive Income					
Deferred Tax Effect on Revaluation Gain	-	(391,880)	-	-	(391,880)
Actuarial Gain on Gratuity Valuation	-	-	-	(15,641)	(15,641)
Deferred Tax Effect on Gratuity Valuation	-	-	-	4,692	4,692
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	5,712	-	5,712
Total Comprehensive Income for the Year	-	(391,880)	5,712	288,289	(97,879)
Transactions with Owners in their capacity as Owners					
Shares issued at Rights Issue	226,432	-	-	-	226,432
Rights Issue Expenses	-	-	-	(2,056)	(2,056)
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)
	226,432	-	-	(171,420)	55,012
Balance as at 31st March 2023 - Audited	1,142,798	1,742,664	6,312	2,812,305	5,704,079
Net Profit for the year ended 31 March 2024	-	-	-	232,472	232,472
Other Comprehensive Income					
Net Gain/ (Loss) on Gratuity valuation	-	-	-	-	-
Deferred Tax Effect on Actuarial Loss	-	-	-	-	-
Net Gain/ (Loss) on Land and Building valuation	-	-	-	-	-
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(6,971)	-	(6,971)
Actuarial Gain on Gratuity Valuation	-	-	-	1,931	1,931
Deferred Tax Effect on Gratuity Valuation	-	-	-	579	579
Total Comprehensive Income for the year ended 31 March 2024	-	-	(6,971)	234,982	228,011
Transactions with Owners in their capacity as Owners					
Rights Issue Expenses	-	-	-	(557)	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)
	-	-	-	(83,333)	(83,333)
Balance as at 31st March 2024	1,142,798	1,742,664	(659)	2,963,955	5,848,758

Consolidated Statement of Cash Flows

	Group		Company	
	Unaudited Year Ended 31/03/2024 Rs '000	Audited Year Ended 31/03/2023 Rs '000	Unaudited Year Ended 31/03/2024 Rs '000	Audited Year Ended 31/03/2023 Rs '000
Cash Flows from/ (Used in) Operating Activities				
Net Profit Before Income Tax Expenses	673,436	1,060,324	293,936	553,932
Adjustments for :				
Inventory Write-off/(Write in)	26,519	7,018	18,538	3,920
Bad Debts Write-off	49,230	68,789	39,241	(7,416)
Depreciation Charge	442,673	389,264	230,162	212,151
Amortisation of Right of use assets	124,577	116,248	124,577	116,248
Finance Income	(112,883)	(207,247)	(171,816)	(294,804)
Finance Cost	144,669	87,898	147,984	61,999
Amortisation of Deferred Rent Expenses/(Income)	-	-	(1,890)	(1,000)
(Profit)/ Loss on Disposal of Property, Plant and Equipment	(17,755)	-	(1,550)	-
(Profit)/ Loss on Disposal of Financial Instruments	-	-	(2,079)	-
Fair value (Gain)/Loss on Financial Instruments	(103,176)	(29,970)	-	(3,546)
Unclaimed Dividends	(1,113)	-	(1,113)	-
Gain identified on a Termination of a Lease	(4,369)	-	(4,369)	-
Creditors written back	(160)	-	-	-
Unclaimed VAT	19,814	-	-	-
Reversal of provisions	-	(24,816)	-	-
Impairment on Receivables	-	2,171	-	-
Provision for Defined Benefit Plans	57,627	41,212	50,804	36,052
Operating Profit before Working Capital Changes	1,299,089	1,510,891	722,425	677,536
(Increase)/Decrease in Inventories	152,820	(192,001)	146,796	(117,943)
(Increase)/Decrease in Trade and Other Receivables	330,379	(509,974)	130,061	(115,936)
Increase/(Decrease) in Trade and Other Payables	133,939	(340,724)	114,470	(425,754)
(Increase)/Decrease Related Party Dues	130,337	(8,194)	286,540	(68,393)
Cash Generated from Operations	2,046,564	459,998	1,400,292	(50,490)
Finance Cost Paid	(144,669)	(55,683)	(147,984)	(29,784)
Defined Benefit Plan Costs Paid	(35,369)	(31,726)	(27,807)	(25,754)
Income Tax/WHT Paid	(234,267)	(264,363)	(60,186)	(129,869)
Net Cash from Operating Activities	1,632,259	108,226	1,164,315	(235,897)
Cash Flows from/ (used in) Investing Activities				
Acquisition of Property, Plant and Equipment	(1,785,060)	(2,218,525)	(1,304,621)	(1,852,868)
Purchase of Intangible Assets	(1,600)	-	-	-
Proceeds from Sale of Property, Plant and Equipment	6,430	-	1,550	-
Proceeds on Sale of Shares/Units	80,728	-	-	-
(Acquisition)/ Disposal of other Investments	449	691,749	(43,144)	624,537
Income from Investments	112,883	207,247	171,816	294,804
Net Cash Flows from/ (used in) Investing Activities	(1,586,170)	(1,319,529)	(1,174,399)	(933,527)
Cash Flows from/ (used in) Financing Activities				
Receipts from Interest Bearing Loans and Borrowings	375,000	875,000	360,000	1,260,000
Re-payments to Interest Bearing Loans and Borrowing	(251,202)	(206,771)	(194,711)	(149,541)
Lease Rent Payment	(161,667)	(142,916)	(161,668)	(142,916)
Proceeds on Shares issued at Rights Issue	-	226,432	-	226,432
Changes in Non-controlling interest on issue of shares by subsidiary	-	5,860	-	-
Right Issue Expenses	(557)	(2,056)	(557)	(2,056)
Dividends Paid	(116,578)	(258,553)	(82,776)	(169,364)
Net Cash Flows from/ (used in) Financing Activities	(155,004)	496,996	(79,712)	1,022,555
Net Increase/ (Decrease) in Cash and Cash Equivalents	(108,915)	(714,307)	(89,796)	(146,868)
Cash and Cash Equivalents at the Beginning of the Year	(62,884)	651,423	(112,100)	34,768
Cash and Cash Equivalents at the End of the Period	(171,799)	(62,884)	(201,896)	(112,100)
Analysis of Cash and Cash Equivalents				
Bank Overdraft	(542,805)	(483,403)	(413,050)	(387,321)
Cash in Hand and at Bank	371,006	420,519	211,154	275,221
	(171,799)	(62,884)	(201,896)	(112,100)

Explanatory Notes

01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the year ended 31 March 2024, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the year ended 31 March 2024 were authorised for issue by the Board of Directors on 29th May 2024.

04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

4.1 Basis of preparation

The interim financial statements for the year ended 31 March 2024 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2024.

4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the nine months were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Investments in quoted shares, Investments in Debentures and Refundable deposits are classified under non current financial assets while Investments in Unit Trusts, Investment in quoted shares (Trading) and Investments in Fixed Deposits are classified under current financial assets.

Recurring Fair Value Measurement As at 31st March 2024	Group				Company			
	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.
Fair Value through Other Comprehensive Income								
Equity Shares in Listed Companies	22,049	-	-	22,049	666	-	-	666
Equity Shares in Non-Listed Companies	-	-	15,565	15,565	-	-	49,304	49,304
Investment in Debentures	-	193,031	-	193,031	-	-	-	-
	22,049	193,031	15,565	230,645	666	-	49,304	49,970
At Amortized Cost								
Refundable Deposits	-	-	58,748	58,748	-	-	57,900	57,900
	-	-	58,748	58,748	-	-	57,900	57,900
Total	22,049	193,031	74,313	289,393	666	-	107,204	107,870

Recurring Fair Value Measurement As at 31st March 2024	Group				Company			
	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.	Level 01 Rs.	Level 02 Rs.	Level 03 Rs.	Total Rs.
Fair Value through Profit or Loss								
Equity Shares in Listed Companies	230,519	-	-	230,519	-	-	-	-
Investments in Unit	444,337	-	-	444,337	45,529	-	-	45,529
	674,856	-	-	674,856	45,529	-	-	45,529
At Amortized Cost								
Refundable Deposits	-	-	446	446	-	-	-	-
Fixed Deposits	-	-	212,903	212,903	-	-	-	-
	-	-	213,349	213,349	-	-	-	-
Total	674,856	-	213,349	888,205	45,529	-	-	45,529

05. Capital Commitments

The Vision 2022 redevelopment project has been successfully completed, with the exception of the dry finishing work at the Wellness Centre and the extended eye clinic. The Main Constructor for the Vision 2022 is M/s Tudawe Brothers (Pvt) Ltd that is a Related Party to the Company.

06. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements other than what is disclosed in the Annual Report 2022/2023.

07. Events occurring after the Balance Sheet date

The EGM for the proposed Rights Issue was held on 14th May 2024, to raise Rs.550 Mn to settle high priced borrowings as announced to the Colombo Stock Exchange

08. Related party transactions for the year ended 31 March 2024 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

09. The company has reclassified the inter group loan of Rs. 510mn from "Interest Bearing Borrowings" to "Amount due to Related Parties" for better and fair presentation.

10. Disclosures on use of proceeds on Rights Issue

Objective number	Objective as per Circular	Amount allocated as per Circular in LKR	Proposed date of Utilization as per Circular	Amount allocated from proceeds in LKR	% of total proceeds	Amount utilized in LKR	% of utilization against allocation
1	Part financing of the cost escalation on capital expenditure of the "Vision 2022" project	Rs. 226,431,675/-	Funds would be utilized immediately upon allotment of shares in the Rights Issue	Rs. 226,431,675/-	100%	Rs. 226,431,675/-	100%

Related Party Transactions

For the year ended 31 March 2024

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs'000
Durdans Management Services Ltd	Ultimate Parent	Management fee Providing utilities and other cost Dividend paid	Recurrent Recurrent Recurrent	45,413 4 49,584
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend Received Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	43,400 139,185 556,275 138,646 88,933 154,181 1,857
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend Received Purchases of Drugs and consumables Receiving of medical services	Recurrent Recurrent Recurrent Recurrent Recurrent Recurrent	6,196 22,746 180,923 23,860 7,129 1,762
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rent Received Providing utilities and other cost	Recurrent Recurrent	22,869 9,359
Ceygen Biotech (Pvt) Ltd	Subsidiary	Providing utilities and other cost Rent Received Purchases of Drugs and consumables	Recurrent Recurrent Recurrent	18 1,950 77
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Sale of Drugs and consumables Purchases of Drugs and consumables	Recurrent Recurrent	1,199 - 186,766

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs'000
Tudawe Brothers (Pvt) Ltd	Affiliate	Vision 2022 Construction Cost	Non Recurrent	494,236
Tudawe Engineering Services (Pvt) Ltd	Affiliate	Vision 2022 Construction Cost	Non Recurrent	36,585

Share Information

Number of Shares Represented in Stated Capital

Voting Shares	27,122,726
Non-Voting Shares	8,867,044
Total	35,989,770

Public Shareholding as at 31st March 2024

	Voting	Non-Voting
Number of shareholders	2,304	1,259
Number of shares	6,726,723	3,044,804
Holding Percentage	24.80%	34.34%
Float Adjusted Market Capitalisation (Rs Mn)	699	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

Directors' and Chief Executive Officer's Shareholding as at 31st March 2024

	Number of Shares	
	Voting	Non-Voting
Mr. A. E. Tudawe	235,152	-
Mr. U. D. Tudawe	181,279	-
Dr A. D. P. A. Wijegoonewardene	234,368	-
Mr. Y. N. R. Piyasena	523,096	-
Mr. A. D. B. Talwatte	1,062	-
Mr. A.V.R. De Silva Jayatilleke	106	-
Mr. A.S. Tudawe	51	1,062
Mr. S. Renganathan	-	-
Mr. H.M.A. Jayasinghe	-	-

Market Prices recorded during the Quarter

	Highest Traded Price		Lowest Traded Price		Last Traded Price	
	2023/24 Rs.	2022/23 Rs.	2023/24 Rs.	2022/23 Rs.	2023/24 Rs.	2022/23 Rs.
Voting	132.00 22/03/2024	151.50 19/01/2023	112.00 25/03/2024	125.50 24/01/2023	119.75 28/03/2024	132.25 31/03/2023
Non - Voting	110.00 30/01/2024	122.75 14/02/2023	92.20 06/03/2024	85.00 24/03/2023	101.75 28/03/2024	95.40 30/03/2023

Per Share Ratios

	Group		Company	
	As at 31/03/2024 Rs.	As at 31/03/2023 Rs.	As at 31/03/2024 Rs.	As at 31/03/2023 Rs.
Earnings Per Share	11.81	16.71	6.46	8.70
Net Asset Per Share	225.40	229.01	162.51	168.01

Top 20 Shareholders Listed as at 31 March 2024
Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	18,628,342	68.68
Lawrance Tudawe Management Services (Pvt) Ltd	do	637,581	2.35
Mr. D.G. Wijemanna	do	600,935	2.22
Mr. R.P. Weerasooriya	do	572,149	2.11
Mr. Deen Mohamed Fazal Aslam	do	526,000	1.94
Mr. Y. N. R. Piyasena	do	523,096	1.93
Galle Face Capital Partners PLC	do	447,774	1.65
Mr. Merrill J. Fernando (Deceased)	do	390,500	1.44
Cargo Boat Development Company PLC	do	324,577	1.20
MJF Holdings (Pvt) Ltd	do	287,917	1.06
Mr. A. E. Tudawe	do	235,152	0.87
Dr. A. D. P. A. Wijegoonewardene	do	234,368	0.86
Mr. U. D. Tudawe	do	181,279	0.67
Mr. H. L. Tudawe	do	175,433	0.65
Mr. A. D. Tudawe	do	172,108	0.63
Mr. P. V. Tudawe	do	166,789	0.61
Commercial Bank of Ceylon PLC A/C No. 04	do	88,187	0.33
Merrill J Fernando & Sons (Pvt) Ltd	do	80,914	0.30
Mr. G. A. Tudawe	do	77,576	0.29
E.W. Balasuriya & Co. (Pvt) Ltd	do	75,256	0.28
		24,425,933	90.07

Non-Voting Shareholders

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	2,929,948	33.04
Employees' Provident Fund	do	1,154,371	13.02
MJF Holdings (Pvt) Ltd	do	636,061	7.17
E. W. Balasuriya & Co. (Pvt) Ltd	do	351,282	3.96
Mr. D. Ratnayake	do	156,045	1.76
Tudawe Engineering Services (Pvt) Ltd	do	97,735	1.10
Mr. D. A. Cabraal	do	87,656	0.99
Mr. S. S. Sithambaranathan	do	82,563	0.93
Mr. A. H. Munasinghe	do	80,000	0.90
Mr. A. D. Tudawe	do	75,597	0.85
Mr. P. S. De Mel	do	75,248	0.85
Ms. T. T. Weerasinghe	do	70,485	0.79
Commercial Bank of Ceylon PLC A/C No. 04	do	64,918	0.73
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	63,750	0.72
Mr. D.P. L. De Mel	do	62,589	0.71
Saman Villas Limited	do	62,115	0.70
Mr. D. G. Wijemanna	do	60,000	0.68
Mr. G. D. M. Ranasinghe	do	55,000	0.62
Mr. U. D. Wickremesooriya	do	53,130	0.60
Mr. H. A. Cabraal	do	53,125	0.60
		6,271,618	70.73

CEYLON HOSPITALS PLC

CORPORATE INFORMATION

Name of Company

Ceylon Hospitals PLC

Brand Name

DURDANS

Legal Form

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

Company Registration Number

PQ 113

Stocks Exchange Listing

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

Registered Office

No.03, Alfred Place, Colombo 03.

Bankers

Bank of Ceylon
Commercial Bank of Ceylon PLC
DFCC Bank PLC
Hatton National Bank PLC
National Development Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Seylan Bank PLC
Union Bank of Colombo PLC
People's Bank

Auditors

Messers.B.R.De.Silva & Co.
Chartered Accountants
No. 22/4,Vijaya Kumaratunga Mawatha
Colombo 05.

Lawyers

Mr. D.F.R. Jayamaha
Hector Jayamaha Law Office,
No.228,Thimbirigasyaya Road,
Colombo 05.

Secretaries

Nexia Corporate Consultants (Pvt) Ltd
No. 130, Level 02, Nawala Road,
Narahenpita. Colombo 05.

Registrars

S S P Corporate Services (Pvt) Ltd
546, Galle Road,
Colombo 03.